339091-08-6

Basic information

• Product Name: 9-(2'', 3'', 5''-TRI-O-BENZOYL-β-L-RIBOFURANOSYL)-2, 6-DICHLOROPURINE
• Synonyms: 9-(2'', 3'', 5''-TRI-O-BENZOYL-β-L-RIBOFURANOSYL)-2, 6-DICHLOROPURINE
• CAS NO: 339091-08-6
• Molecular Formula: C31H22Cl2N4O7
• Molecular Weight: 633.442
• Mol File: 339091-08-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9-(2'', 3'', 5''-TRI-O-BENZOYL-β-L-RIBOFURANOSYL)-2, 6-DICHLOROPURINE(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(2'', 3'', 5''-TRI-O-BENZOYL-β-L-RIBOFURANOSYL)-2, 6-DICHLOROPURINE(339091-08-6)
• EPA Substance Registry System: 9-(2'', 3'', 5''-TRI-O-BENZOYL-β-L-RIBOFURANOSYL)-2, 6-DICHLOROPURINE(339091-08-6)

Safety Data

• Hazardous Substances Data: 339091-08-6(Hazardous Substances Data)

Upstream product

• 5451-40-1 2,6 dichloropurine 
• 14215-97-5 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 55057-34-6 2,3,5-tri-O-acetyl-α-D-ribofuranosyl bromide 
• 39925-22-9 2,3,5-Tris-O-acetyl-β-D-ribofuranosyl bromide 
• 5451-40-1 2,6-dichloro-7H-purine 
• 5991-01-5 2,3,5-(tri-O-benzoyl)-D-ribofuranosyl chloride 
• 69-89-6 xanthine 
• 171887-02-8 2-amino-5-{[(dimethylamino)methylene]amino}-4,6-dichloropyrimidine 
• 918800-27-8 p-tolyl 2,3,5-tri-O-benzoyl-1-thio-β-D-ribofuranoside 
• 4348-68-9 2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl bromide 

Downstream Products

• 119530-56-2 2-Chloro-2',3'-didehydro-2',3'-dideoxyadenosine 
• 162684-35-7 NNC 21-0136 
• 155769-07-6 2-methoxy-N-[(R)-1-phenoxy-2-propyl]adenosine 
• 1000980-71-1 ((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol 
• 1000980-71-1 ((3aR,4R,6R,6aR)-6-(2-chloro-6-(3-iodobenzylamino)9H-purine-9-yl) 2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 163152-31-6 MRS 542 

Relevant articles and documents

Application of 2,6-diazidopurine derivatives in the synthesis of thiopurine nucleosides

2,6-Diazidopurine derivatives undergo double azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reactions to give 2,6-bis-(triazolyl)purine analogs, which undergo selective nucleophilic aromatic substitution with various thiols at C(6). This synthetic sequenc

METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES

The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type reagent, the functi

A One-Pot Synthesis of Highly Functionalized Purines

Highly substituted purines were synthesized in good to high yields through a one-pot straightforward metal-free scalable method, using the Traube synthesis adapted to Vilsmeier-type reagents. From 5-amino-4-chloropyrimidines, new 9-aryl-substituted chloropurines and intermediates for peptide nucleic acid synthesis were prepared. Variant procedures allowing a rapid synthesis of ribonucleosides and 7-benzylpurine from 5-amidino-6-aminopyrimidines are also reported to illustrate the high potential of this versatile toolbox. This route appears to be particularly interesting in the field of nucleic acids for a direct and rapid access to various new 8-alkylpurine nucleosides.

Novel Adenine Derivatives and the Use Thereof

The present invention refers to novel adenine derivatives and their polymer relates to about number, product of formula 1 is provided novel adenine derivatives or pharmaceutically acceptable salt thereof, including same composition for the prevention or treatment of neurodegenerative disease are disclosed. The present invention according to adenosine A3 receptor agonist novel adenine derivatives and their pharmaceutically acceptable salts as number, inflammatory cell (12 and ifnγ (microglia), macrophages (macrophages) on neutrophil (neutrophil), or the like) disease site (mobile, migration or infiltration) and activity has a number action billion for migration. In addition, the present invention according to conventional publicly known adenosine A3 receptor agonist is adenine derivatives of the Ginko experiment model number as the effective number and treating traumatic billion extent significant advantages over a support, and a significant effect in red after drug administration even after 10, through long-term survival even traumatic brain have been identified bar makes it possible to reduce cerebral ischemia, including ischemic number can be utilized as useful in the treatment and prevention of neurodegenerative disease. (by machine translation)

Novel Polymorph of Regadenoson

The invention provides a novel polymorph of Regadenoson. More particularly, the invention provides propylene glycol solvate of Regadenoson. The invention also provides a process for the preparation of propylene glycol solvate of Regadenoson.

Novel Adenine Derivatives and the Use Thereof

The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof, and to a composition containing the same for preventing or treating degenerative brain disease. The novel adenine derivative and the pharmaceutically acceptable salt thereof according to the present invention are adenosine A3 receptor agonists, and have an action of inhibiting the migration (or infiltration) of inflammatory cells (microglia, macrophages, neutrophils, etc.), to disease areas and the activities thereof. In addition, the adenine derivative according to the present invention was verified to suppress and treat brain injury more remarkably when compared with the known adenosine A3 receptor agonists in a cerebral ischemia experimental model, exhibit a significant effect by drug administration 10 hours after cerebral infarction, and allow long-term survival in spite of brain injury due to cerebral ischemia, and thus can be useful as an agent for treating and preventing degenerative brain disease including stroke.(AA,BB,CC,DD) Chemical formula 5COPYRIGHT KIPO 2015

Novel Process for the Preparation of (1-pyrazole-4-yl)-N-methylcarboxamide

The present invention relates to a novel process for the preparation of (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide.

A general method for N-glycosylation of nucleobases promoted by (p-Tol)2SO/Tf2O with thioglycoside as donor

Based on a preactivation strategy using the (p-Tol)2SO/Tf2O system, a series of nucleosides were synthesized by coupling various thioglycosides with pyrimidines and purines under mild conditions. High yields and excellent β-stereoselectivities were obtained with either armed or disarmed N-glycosylation donors by tuning the amount of (p-Tol)2SO additive.

2'-deoxy-L-nucleosides

This invention provides processes for the preparation of compounds having the structure: wherein X and Y are same or different, and H, OH, OR, SH, SR, NH2, NHR′, or NR′R″Z is H, F, Cl, Br, I, CN, or NH2. R is hydrogen, halogen, lower alkyl of C1-C6 or aralkyl, NO2, NH2, NHR′, NR′R″, OH, OR, SH, SR, CN, CONH2, CSNH2, CO2H, CO2R′, CH2CO2H, CH2CO2R′, CH═CHR, CH2CH═CHR, or C═CR. R′ and R″ are same or different, and lower alkyl of C1-C6. R13 is hydrogen, alkyl, acyl, phosphate (monophosphate, diphosphate, triphosphate, or stabilized phosphate) or silyl; and